Blood Cancer Research Assays
Deep molecular profiling of blood cancers
Archer Blood Cancer research assays leverage a powerful technology for error-corrected next-generation sequencing for high sensitivity oncogene profiling.
Archer® Blood Cancer research assays detect various driver mutations in hematologic malignancies, such as myeloid and lymphoid diseases, by targeted next-generation sequencing (NGS).
This approach combines FusionPlex® and VariantPlex® panels to characterize gene fusions, point mutations, copy number variations (CNVs) and other variant types from a single sample.
All Archer panels are powered by Anchored Multiplex PCR (AMP™) chemistry and thus follow the same workflow for maximum lab efficiency.
Comprehensive Tumor Profiling
Get the most information from your sample - fusions, CNVs, SNVs, indels and expression levels.
Error Correction & Quantit ative Analysis
Molecular barcode sequences ligated prior to amplification enable duplicate read binning and advanced error correction for confident variant calls.
Sensitive & Specific Variant Detection
Powerful bioinformatics combined with orthogonal variant verification.
Our Blood Cancer Research Assays
Archer® FusionPlex RUO panels generate target-enriched libraries from RNA to characterize gene fusions, splice variants, SNVs, indels and relative expression levels by next-generation sequencing (NGS) on Illumina® and Ion Torrent™ platforms.
Archer® VariantPlex RUO panels combine patented enrichment chemistry, an easy workflow and powerful bioinformatics to generate target-enriched libraries from DNA to confidently detect copy number variations (CNVs), single-nucleotide variants (SNVs) and indels by next-generation sequencing (NGS).